{
    "clinical_study": {
        "@rank": "149514", 
        "acronym": "SMNRx - CS2", 
        "arm_group": [
            {
                "arm_group_label": "ISIS-SMNRx Dose level 1", 
                "arm_group_type": "Experimental", 
                "description": "Administered three times by intrathecal injection"
            }, 
            {
                "arm_group_label": "ISIS-SMNRx:  Dose level 2", 
                "arm_group_type": "Experimental", 
                "description": "Administered three times by intrathecal injection"
            }, 
            {
                "arm_group_label": "ISIS-SMNRx:  Dose level 3", 
                "arm_group_type": "Experimental", 
                "description": "Administered two times by intrathecal injection"
            }, 
            {
                "arm_group_label": "Experimental:   ISIS-SMNRx: Dose level 4", 
                "arm_group_type": "Experimental", 
                "description": "Administered three times by intrathecal injection"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will test the safety, tolerability, and pharmacokinetics of escalating doses of\n      ISIS-SMNRx administered into the spinal fluid either two or three times over the duration of\n      the trial, in patients with Spinal Muscular Atrophy."
        }, 
        "brief_title": "An Open-label Safety, Tolerability and Dose-range Finding Study of Multiple Doses of ISIS SMNRx in Patient With Spinal Muscular Atrophy", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Spinal Muscular Atrophy", 
        "condition_browse": {
            "mesh_term": [
                "Muscular Atrophy", 
                "Muscular Atrophy, Spinal", 
                "Atrophy"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study will test the safety, tolerability, and pharmacokinetics of escalating doses of\n      ISIS-SMNRx administered multiple times over the duration of the trial, as intrathecal\n      injections.  Four dose levels will be evaluated sequentially.  Each dose level will be\n      studied in a cohort of 8 patients, where all patients will receive active drug."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Genetic documentation of 5q SMA (homozygous gene deletion or mutation)\n\n          -  Clinical signs attributable to Spinal Muscular Atrophy\n\n          -  Males and females 2 to 15 years of age\n\n          -  Able to complete all study procedures, measurements, and visits and parent/patient\n             has adequately supportive psychosocial circumstances, in the opinion of the\n             Investigator\n\n          -  Estimated life expectancy > 2 years from Screening\n\n          -  Meets age-appropriate institutional criteria for use of anesthesia/sedation, if use\n             is planned for study procedure\n\n        Exclusion Criteria:\n\n          -  Respiratory insufficiency defined by the medical necessity for invasive or\n             non-invasive ventilation during a 24 hour period\n\n          -  Medical necessity for a gastric feeding tube, where the majority of feeds are given\n             by this route, as assessed by the Site Investigator\n\n          -  Previous scoliosis surgery that would interfere with the lumbar puncture injection\n             procedure\n\n          -  Hospitalization for surgery (i.e. scoliosis surgery) or pulmonary event within 2\n             months of screening or planned during the duration of the study\n\n          -  Presence of an untreated or inadequately treated active infection requiring systemic\n             antiviral or antimicrobial therapy at any time during the screening period\n\n          -  History of brain or spinal cord disease that would interfere with lumbar puncture\n             procedures or CSF circulation\n\n          -  Presence of an implanted shunt for the drainage of CSF or an implanted CNS catheter\n\n          -  History of bacterial meningitis\n\n          -  Dosing with ISIS 396443 in clinical study ISIS 396443-CS1 Cohorts 2, 3, or 4\n\n          -  Dosing with ISIS 396443 in clinical study ISIS 396443 - CS10\n\n          -  Clinically significant abnormalities in hematology or clinical chemistry parameters\n\n          -  Treatment with investigational drug, biological agent, or device within 1-month of\n             Screening or 5 half-lives of study agent, whichever is longer.  Treatment with\n             valproate or hydroxyurea within 3-months of screening.  Any history of gene therapy\n             or cell transplantation\n\n          -  Ongoing medical condition that would interfere with the conduct and assessments of\n             the study.  Examples are medical disability (e.g. wasting or cachexia, severe anemia,\n             etc.)that would interfere with the assessment of safety or would compromise the\n             ability of the patient to undergo study procedures."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "15 Years", 
            "minimum_age": "2 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 8, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01703988", 
            "org_study_id": "ISIS 396443 - CS2"
        }, 
        "intervention": {
            "arm_group_label": [
                "ISIS-SMNRx Dose level 1", 
                "ISIS-SMNRx:  Dose level 2", 
                "ISIS-SMNRx:  Dose level 3", 
                "Experimental:   ISIS-SMNRx: Dose level 4"
            ], 
            "description": "Single intrathecal injection for each dose", 
            "intervention_name": "ISIS-SMNRx", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Spinal Muscular Atrophy", 
            "SMA", 
            "SMN", 
            "SMNRx", 
            "ISIS-SMNRx", 
            "ISIS 396443"
        ], 
        "lastchanged_date": "April 4, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02115"
                    }, 
                    "name": "Boston Children's Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10032"
                    }, 
                    "name": "Columbia University Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75207"
                    }, 
                    "name": "UT Southwestern Medical Center - Children's Medical Center Dallas"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84132"
                    }, 
                    "name": "University of Utah School of Medicine"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "An Open-Label, Dose Escalation Study to Assess the Safety, Tolerability and Dose-Range Finding of Multiple Doses of ISIS 396443 Delivered Intrathecally to Patients With Spinal Muscular Atrophy", 
        "other_outcome": {
            "description": "- The observed CSF drug concentration", 
            "measure": "CSF Pharmacokinetics (See clarification.)", 
            "safety_issue": "No", 
            "time_frame": "CSF at Day 1, Day 29, and Day 85"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The number of participants with adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "Patricipants will be followed for the duration of the study; an expected 36 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01703988"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "the maximal observed plasma drug concentration (Cmax)\nthe time to reach Cmax in plasma (Tmax)\nthe area under the plasma concentrations time curve from the time of the   intrathecal dose to the last collected sample (20 hours after dosing)", 
            "measure": "Plasma Pharmacokinetics (See clarification.)", 
            "safety_issue": "No", 
            "time_frame": "Plasma at 1, 2, 4, 6 and 20 hours after dosing"
        }, 
        "source": "Isis Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Isis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}